World's Best Scientists 2026 revealed!
Geert Leroux-Roels

Geert Leroux-Roels

D-Index & Metrics

Immunology

D-Index
80
Citations
20761
World Ranking
1644
National Ranking
22

Geert Leroux-Roels publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Geert Leroux-Roels sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 456 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Geert Leroux-Roels D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Geert Leroux-Roels sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Geert Leroux-Roels is affiliated with Ghent University in Belgium. Their research spans major areas of Medicine and Immunology and Microbiology, contributing extensively to epidemiology, infectious diseases, immunology, hepatology, and public health disciplines.

The scientist's work involves significant exploration into viral infections and vaccination strategies. Primary research topics include:

  • Influenza Virus Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • Animal Virus Infections Studies

Frequent publication venues reflect a focus on immunology and vaccine-related research. These include:

  • Frontiers in Immunology
  • Vaccine
  • The Lancet Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Vaccine X

Among recent papers by Geert Leroux-Roels are:

  • Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial, 2021, Vaccine
  • Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2, 2021, Wiener klinische Wochenschrift
  • Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials, 2020, The Lancet
  • Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial, 2021, The Lancet Infectious Diseases

Common collaborators include:

  • Isabel Leroux-Roels
  • Gwenn Waerlop
  • Pierre Van Damme
  • Lidia Oostvogels
  • Gianluca Quintini

This researcher's profile demonstrates ongoing work in developing and testing vaccines, especially involving mRNA technology and lipid nanoparticle delivery systems, with an emphasis on prophylactic measures against viral diseases such as rabies, SARS-CoV-2, poliovirus, and hepatitis B.

Best Publications

  • Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

    Isabel Leroux-Roels;Astrid Borkowski;Thomas Vanwolleghem;Mamadou Dramé

  • Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

    Brett D. Lindenbach;Philip Meuleman;Alexander Ploss;Thomas Vanwolleghem

  • Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations.

    Hélène Quach;Maxime Rotival;Maxime Rotival;Julien Pothlichet;Julien Pothlichet;Yong-Hwee Eddie Loh;Yong-Hwee Eddie Loh

  • Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.

    Philip Meuleman;Louis Libbrecht;Rita De Vos;Bernard de Hemptinne

  • Unmet needs in modern vaccinology: Adjuvants to improve the immune response

    Geert Leroux-Roels

  • Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.

    Philip Meuleman;Joseph Hesselgesser;Matthew Paulson;Thomas Vanwolleghem

  • Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness

    Ann R. Falsey;Janet E. McElhaney;Jiri Beran;Gerrit A. van Essen

  • Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

    Pierre Vandepapelière;Yves Horsmans;Philippe Moris;Marcelle Van Mechelen

  • Hepatitis A booster vaccination: is there a need?

    Pierre Van Damme;J Banatvala;O Fay;S Iwarson

  • Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.

    Michael P. Cooreman;Geert Leroux-Roels;Wilma P. Paulij

  • Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy

    Lieven Stuyver;Caroline Van Geyt;Sija De Gendt;Georges Van Reybroeck

  • Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

    Pierre Vandepapelière;George K K Lau;Geert Leroux-Roels;Yves Horsmans

  • Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant

    Artur Kaul;Ilka Woerz;Philip Meuleman;Geert Leroux-Roels

  • Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.

    Isabel Leroux-Roels;Roger Bernhard;Pascal Gérard;Mamadou Dramé

  • Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

    S Thoelen;P Van Damme;C Mathei;Geert Leroux-Roels

  • Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity

    Joe Grove;Thierry Huby;Zania Stamataki;Thomas Vanwolleghem

  • Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation.

    R J Burnett;G François;M C Kew;G Leroux-Roels

  • Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

    Isabel Leroux-Roels;François Roman;Sheron Forgus;Cathy Maes

  • Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial

    Isabel Leroux-Roels;Sheron Forgus;Fien De Boever;Frédéric Clement

  • Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.

    Thomas Vanwolleghem;Jens Bukh;Jens Bukh;Jens Bukh;Philip Meuleman;Isabelle Desombere

Frequent Co-Authors

Philip Meuleman
Philip Meuleman Ghent University
Joris R. Delanghe
Joris R. Delanghe Ghent University
Geert Maertens
Geert Maertens Biocartis (Belgium)
Jonathan K. Ball
Jonathan K. Ball University of Nottingham
Jens Bukh
Jens Bukh University of Copenhagen
Thomas F. Baumert
Thomas F. Baumert University of Strasbourg
Tania Roskams
Tania Roskams KU Leuven
Robert W. Sauerwein
Robert W. Sauerwein Radboud University
Riccardo Cortese
Riccardo Cortese Schering-Plough
Alfredo Nicosia
Alfredo Nicosia University of Naples Federico II

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related healthcare fields can broaden career opportunities. Many students pursue nursing degrees alongside their immunology studies to gain practical skills and clinical knowledge. Programs like accelerated nurse practitioner programs offer a fast-tracked pathway for licensed nurses to advance into specialized practitioner roles.

Non-nursing professionals can also transition into healthcare through 12-month accelerated nursing programs online for non nurses. These programs are designed to equip graduates with essential nursing competencies in a condensed timeline, ideal for those seeking swift career changes.

When selecting a program, accessibility is a key factor. Some students prefer the easiest accelerated nursing programs to get into, balancing admission requirements with quality education. Similarly, easiest lpn programs to get into provide a practical entry point into the nursing profession, offering critical foundational skills with fewer barriers to entry.

Understanding these pathways helps immunology students align their education with evolving healthcare demands and diverse professional roles.

Best Scientists Citing Geert Leroux-Roels

Trending Scientists

Recently Published Articles